The safety and efficacy of AdreView were evaluated in two open-label, multicenter, international trials in 985 patients with NYHA class II or class III heart failure with LVEF ≤35%. A total of 110 patients without a history of heart disease also received a single dose of AdreView. The endpoint for analysis was all-cause mortality, an outcome confirmed by review of an independent adjudication committee. By 12 months following enrollment among the 964 heart failure patients in the efficacy population, 50 (5%) patients had died, 61 (6%) had missing follow-up information and three patients had missing H/M ratios. One-year mortality rates in relation to AdreView H/M ratio were: <1.2: 13.4%; 1.2-1.6: 5.5%; ≥1.6: 1.0%. By 23 months following enrollment (the requirement for designation of two-year follow-up), 96 (10%) patients had died, 201 (21%) patients had missing follow-up information and three patients were missing H/M ratio data. Two-year mortality rates in relation to AdreView H/M ratio were: <1.2: 22.0%; 1.2-1.6: 11.5%; ≥1.6: 3.3%. 2
About Heart Failure
Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through the heart to meet the body's needs.
Nearly 5.1 million Americans suffer from heart failure, and half of these individuals will die within five years.
The total cost of heart failure is estimated to be nearly 32 billion to the US health system.
Patients who have previously suffered from heart failure have a sudden death rate that is six to nine times greater than the general population.
Important Risk and Safety Information about AdreView (Iobenguane I 123 Injection)
AdreView is a radiopharmaceutical indicated for: (1) use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests; and, (2) scintigraphic imaging assessment of sympathetic innervation of the myocardium to assist in the evaluation of adult patients with NYHA class II or class III heart failure and left ventricular ejection fraction ≤35% to help identify patients with one and two-year mortality risks as indicated by an H/M ratio ≥ 1.6. In patients with congestive heart failure (CHF), utility has not been established for selecting therapy, monitoring response to therapy, or to identify a patient with high risk of death.
AdreView is contraindicated in patients with known hypersensitivity to iobenguane or iobenguane sulfate.
WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have followed AdreView administration. Have anaphylactic and hypersensitivity treatment measures available prior to administration.
Benzyl Alcohol Toxicity in Infants:
AdreView contains benzyl alcohol, which may cause serious reactions, in premature or low birth-weight infants.
Patients with Severe Renal Impairment:
As AdreView is cleared by glomerular filtration and is not dialyzable, these patients may have increased radiation exposure and decreased image quality.
Administer thyroid blockade to patients at risk of thyroid accumulation of AdreView.
Drugs that block norepinephrine uptake or deplete norepinephrine stores, such as some antihypertensive agents, may decrease AdreView uptake and may lead to incorrect imaging results. When medically feasible, stop these drugs before AdreView administration.
AdreView may increase release of norepinephrine from chromaffin granules producing transient hypertension.
Individuals with Neurological Diseases that Affect the Sympathetic Nervous System:
Imaging in these patients may show decreased cardiac uptake independent of heart disease.
Serious hypersensitivity reactions have been reported following AdreView administration. The most common adverse reactions in NDA clinical trials - dizziness, rash, pruritis, flushing, headache and injection site reactions - occurred in ≤ 1.3% of patients.
USE IN SPECIFIC POPULATIONS:
Radiopharmaceuticals have potential to cause fetal harm. It is not known whether AdreView can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AdreView should be given to a pregnant woman only if clearly needed.
It is not known whether AdreView is excreted into human milk, however, iodine 123 is excreted into human milk. A decision should be made whether to interrupt nursing after administration of AdreView or not to administer AdreView.
Safety and effectiveness have not been established in pediatric patients < 1 month of age or in any pediatric patients with CHF.
Clinical experience has not identified differences in responses between the elderly and younger patients. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and image interpretation. Consider assessment of renal function in elderly patients prior to AdreView administration.
Prior to AdreView administration, please read the Full Prescribing Information
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.